- Trial phase
- Approved (FDA approval November 22, 2022); pivotal Phase 3 HOPE-B trial completed primary analysis, long-term follow-up
- Time to market
- Approved and on the market since November 2022 (U.S.), commercialized worldwide by CSL Behring, but currently constrained by a temporary global stockout announced March 2026
- Why 3/10
- HEMGENIX is already approved (FDA, Nov 22, 2022) with no pending PDUFA/readout for this molecule in the next ~12 months, the defining binary passed, so the score caps at 3-5; it is set at 3 because the drug is now a minor, largely-monetized royalty/manufacturing revenue line for QURE, whose market value (~$2.3B) and near-term catalysts are driven by the separate AMT-130 program, and the only live HEMGENIX event (resolution of CSL's global stockout) is event-driven, not a scheduled decision.
For QURE holders, stop thinking of HEMGENIX as the thesis: the stock now trades on AMT-130 (Huntington's), BLA submission on track for Q3 2026 and topline 4-year data expected September 2026. Watch HEMGENIX only as a modest cash-flow line: CSL has been in a manufacturing-related temporary global stockout since March 2026 and, as of its July 24, 2026 update, supply was still being actively managed, any resumption announcement or CSL sales disclosure is a minor, non-binary event for QURE (which already sold $375M of its royalty tier to HealthCare Royalty/Sagard).
Price Chart
Executive Summary
HEMGENIX (etranacogene dezaparvovec-drlb), developed by uniQure (Nasdaq: QURE) and commercialized by CSL Behring, is the first FDA-approved gene therapy for hemophilia B (approved Nov 22, 2022) with durable efficacy shown in the pivotal HOPE-B trial. uniQure's economics are modest and partly monetized: it received a $450M upfront from CSL in 2020 plus milestones, then sold its lowest royalty tier for $375M upfront; HEMGENIX-related income is a small part of QURE's ~$16M 2025 total revenue, and the company's value now hinges on its separate Huntington's program (AMT-130). The live commercial overhang is CSL's manufacturing-related temporary global stockout, announced March 17, 2026, with a follow-up July 24, 2026 update confirming supply was still being managed, a real drag on the product's ramp but not a swing factor for QURE stock.
How It Works
A one-time intravenous gene therapy. It uses a harmless, engineered virus (AAV5) to deliver a working copy of the F9 gene into liver cells, so the patient's own liver produces clotting factor IX, aiming to reduce or eliminate the need for lifelong, regular factor IX replacement infusions in adults with hemophilia B.
Trial Status
Approval rests on the HOPE-B Phase 3 trial (largest gene therapy trial in hemophilia B), which showed mean factor IX activity of 39% at six months and 36.7% at 24 months post-infusion; CSL reported 3-year durability, safety and bleed-protection data in December 2023, and later follow-up out to three years post-dose has been presented. The product is now in commercial phase with a global supply interruption under active management.
The Two-Sided Case
Upcoming Catalysts
- Resolution/restoration of HEMGENIX supply, CSL has issued community updates (March 17, 2026 stockout; July 24, 2026 status) and further announcements on availability are the only scheduled-type events specific to this drug
- CSL quarterly/annual net sales disclosures for HEMGENIX and any resulting change in uniQure's royalty/manufacturing revenue line
- Company-level (different drug, but the real QURE drivers): AMT-130 BLA submission on track Q3 2026 and topline four-year AMT-130 data expected September 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
uniQure N.V. 8-K QURE ·Originating report